New trial
Neoadjuvant Treatment With Zanzalintinib for Advanced Thyroid Cancer
- Trial ID
- NCT06959511 on ClinicalTrials.gov
- Cancer type
- Thyroid Cancer
- Published in
- New in Oncology - May 21, 2025
MD Anderson is conducting a trial to assess the safety and effectiveness of zanzalintinib (100 mg daily) followed by surgery in advanced thyroid cancers—both medullary (non-RET mutant) and non-medullary subtypes.
More in thyroid cancer
-
Trial result · Oct 22, 2026 · NCT03899792
Selpercatinib (selective RET inhibitor) posts 53% ORR with 2-year durability in pediatric RET-altered tumors -
Trial result · Aug 13, 2026 · NCT04940052
Dabrafenib + trametinib (BRAF/MEK) cuts progression risk in BRAF V600E thyroid cancer -
Trial result · Aug 13, 2026 · NCT03181100
Atezolizumab (PD-L1) + MAPK-targeted therapy links ATC long survival to “inflamed + differentiated” tumors, not BRAF/RAS status -
Trial result · Jul 8, 2026 · NCT03037385
Pralsetinib (selective RET inhibitor) drives 92% ORR in pretreated RET fusion+ thyroid cancer; 68% ORR in RET-altered MTC -
Trial result · Jul 8, 2026 · NCT03669432
THYRO-RT Finds No Significant LRR Benefit From Adjuvant EBRT in High-Risk Thyroid Cancer